These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

4344 related items for PubMed ID: 17395339

  • 1. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
    Lemesre JL, Holzmuller P, Gonçalves RB, Bourdoiseau G, Hugnet C, Cavaleyra M, Papierok G.
    Vaccine; 2007 May 22; 25(21):4223-34. PubMed ID: 17395339
    [Abstract] [Full Text] [Related]

  • 2. Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes.
    Lemesre JL, Holzmuller P, Cavaleyra M, Gonçalves RB, Hottin G, Papierok G.
    Vaccine; 2005 Apr 22; 23(22):2825-40. PubMed ID: 15780731
    [Abstract] [Full Text] [Related]

  • 3. Lymphocytes of dogs immunised with purified excreted-secreted antigens of Leishmania infantum co-incubated with Leishmania infected macrophages produce IFN gamma resulting in nitric oxide-mediated amastigote apoptosis.
    Holzmuller P, Cavaleyra M, Moreaux J, Kovacic R, Vincendeau P, Papierok G, Lemesre JL.
    Vet Immunol Immunopathol; 2005 Jul 15; 106(3-4):247-57. PubMed ID: 15963823
    [Abstract] [Full Text] [Related]

  • 4. Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals.
    Gradoni L, Foglia Manzillo V, Pagano A, Piantedosi D, De Luna R, Gramiccia M, Scalone A, Di Muccio T, Oliva G.
    Vaccine; 2005 Nov 01; 23(45):5245-51. PubMed ID: 16054272
    [Abstract] [Full Text] [Related]

  • 5. Effective humoral and cellular immunoprotective responses in Li ESAp-MDP vaccinated protected dogs.
    Bourdoiseau G, Hugnet C, Gonçalves RB, Vézilier F, Petit-Didier E, Papierok G, Lemesre JL.
    Vet Immunol Immunopathol; 2009 Mar 15; 128(1-3):71-8. PubMed ID: 19046774
    [Abstract] [Full Text] [Related]

  • 6. Recombinant Forms of Leishmania amazonensis Excreted/Secreted Promastigote Surface Antigen (PSA) Induce Protective Immune Responses in Dogs.
    Petitdidier E, Pagniez J, Papierok G, Vincendeau P, Lemesre JL, Bras-Gonçalves R.
    PLoS Negl Trop Dis; 2016 May 15; 10(5):e0004614. PubMed ID: 27223609
    [Abstract] [Full Text] [Related]

  • 7. Vaccination with plasmid DNA encoding KMPII, TRYP, LACK and GP63 does not protect dogs against Leishmania infantum experimental challenge.
    Rodríguez-Cortés A, Ojeda A, López-Fuertes L, Timón M, Altet L, Solano-Gallego L, Sánchez-Robert E, Francino O, Alberola J.
    Vaccine; 2007 Nov 14; 25(46):7962-71. PubMed ID: 17942199
    [Abstract] [Full Text] [Related]

  • 8. Diminished CD4+/CD25+ T cell and increased IFN-gamma levels occur in dogs vaccinated with Leishmune in an endemic area for visceral leishmaniasis.
    de Lima VM, Ikeda FA, Rossi CN, Feitosa MM, Vasconcelos RO, Nunes CM, Goto H.
    Vet Immunol Immunopathol; 2010 Jun 15; 135(3-4):296-302. PubMed ID: 20132994
    [Abstract] [Full Text] [Related]

  • 9. Identification and characterization of new Leishmania promastigote surface antigens, LaPSA-38S and LiPSA-50S, as major immunodominant excreted/secreted components of L. amazonensis and L. infantum.
    Bras-Gonçalves R, Petitdidier E, Pagniez J, Veyrier R, Cibrelus P, Cavaleyra M, Maquaire S, Moreaux J, Lemesre JL.
    Infect Genet Evol; 2014 Jun 15; 24():1-14. PubMed ID: 24614507
    [Abstract] [Full Text] [Related]

  • 10. Canine Leishmania vaccines: still a long way to go.
    Gradoni L.
    Vet Parasitol; 2015 Feb 28; 208(1-2):94-100. PubMed ID: 25620293
    [Abstract] [Full Text] [Related]

  • 11. Immunogenicity of a multicomponent DNA vaccine against visceral leishmaniasis in dogs.
    Saldarriaga OA, Travi BL, Park W, Perez LE, Melby PC.
    Vaccine; 2006 Mar 10; 24(11):1928-40. PubMed ID: 16310897
    [Abstract] [Full Text] [Related]

  • 12. Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum.
    Rafati S, Nakhaee A, Taheri T, Taslimi Y, Darabi H, Eravani D, Sanos S, Kaye P, Taghikhani M, Jamshidi S, Rad MA.
    Vaccine; 2005 May 25; 23(28):3716-25. PubMed ID: 15882533
    [Abstract] [Full Text] [Related]

  • 13. Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response.
    Ramos I, Alonso A, Marcen JM, Peris A, Castillo JA, Colmenares M, Larraga V.
    Vaccine; 2008 Jan 17; 26(3):333-44. PubMed ID: 18093705
    [Abstract] [Full Text] [Related]

  • 14. Interleukin-12 augments a Th1-type immune response manifested as lymphocyte proliferation and interferon gamma production in Leishmania infantum-infected dogs.
    Strauss-Ayali D, Baneth G, Shor S, Okano F, Jaffe CL.
    Int J Parasitol; 2005 Jan 17; 35(1):63-73. PubMed ID: 15619517
    [Abstract] [Full Text] [Related]

  • 15. [Interpretation of laboratory data during cryptic leishmaniasis in dog].
    Gravino AE.
    Parassitologia; 2004 Jun 17; 46(1-2):227-9. PubMed ID: 15305723
    [Abstract] [Full Text] [Related]

  • 16. Serological evaluation of experimentally infected dogs by LicTXNPx-ELISA and amastigote-flow cytometry.
    Silvestre R, Santarém N, Cunha J, Cardoso L, Nieto J, Carrillo E, Moreno J, Cordeiro-da-Silva A.
    Vet Parasitol; 2008 Nov 25; 158(1-2):23-30. PubMed ID: 18848397
    [Abstract] [Full Text] [Related]

  • 17. Peripheral blood mononuclear cell supernatants from asymptomatic dogs immunized and experimentally challenged with Leishmania chagasi can stimulate canine macrophages to reduce infection in vitro.
    Rodrigues CA, Batista LF, Teixeira MC, Pereira AM, Santos PO, de Sá Oliveira GG, de Freitas LA, Veras PS.
    Vet Parasitol; 2007 Feb 28; 143(3-4):197-205. PubMed ID: 17045743
    [Abstract] [Full Text] [Related]

  • 18. Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis.
    Fujiwara RT, Vale AM, França da Silva JC, da Costa RT, Quetz Jda S, Martins Filho OA, Reis AB, Corrêa Oliveira R, Machado-Coelho GL, Bueno LL, Bethony JM, Frank G, Nascimento E, Genaro O, Mayrink W, Reed S, Campos-Neto A.
    Vet Res; 2005 Feb 28; 36(5-6):827-38. PubMed ID: 16120256
    [Abstract] [Full Text] [Related]

  • 19. Clinical value of anti-Leishmania (Leishmania) chagasi IgG titers detected by flow cytometry to distinguish infected from vaccinated dogs.
    de Andrade RA, Reis AB, Gontijo CM, Braga LB, Rocha RD, Araújo MS, Vianna LR, Martins-Filho OA.
    Vet Immunol Immunopathol; 2007 Mar 15; 116(1-2):85-97. PubMed ID: 17287029
    [Abstract] [Full Text] [Related]

  • 20. The FML-vaccine (Leishmune) against canine visceral leishmaniasis: a transmission blocking vaccine.
    Saraiva EM, de Figueiredo Barbosa A, Santos FN, Borja-Cabrera GP, Nico D, Souza LO, de Oliveira Mendes-Aguiar C, de Souza EP, Fampa P, Parra LE, Menz I, Dias JG, de Oliveira SM, Palatnik-de-Sousa CB.
    Vaccine; 2006 Mar 20; 24(13):2423-31. PubMed ID: 16386824
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 218.